Evidence map›Paper›PMID 39604505›Full record

ArticleMolecular psychiatry2025

Dysregulation of the mTOR-FMRP pathway and synaptic plasticity in an environmental model of ASD.

Muna L Hilal, Eleonora Rosina, Giorgia Pedini, Leonardo Restivo, Claudia Bagni

Abstract read
In one paragraph

Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Blood-based proteomic signature of amyloidosis: identification of novel regulators of amyloid load.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Designing Neural Dynamics: From Digital Twin Modeling to Regeneration.International journal of molecular sciences · 2025
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Muna L Hilal *Department of Fundamental Neurosciences, University of Lausanne, 1005, Lausanne, Switzerland.
Eleonora Rosina *Department of Fundamental Neurosciences, University of Lausanne, 1005, Lausanne, Switzerland.
Giorgia PediniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133, Rome, Italy.
Leonardo RestivoDepartment of Fundamental Neurosciences, University of Lausanne, 1005, Lausanne, Switzerland.
Claudia BagniDepartment of Fundamental Neurosciences, University of Lausanne, 1005, Lausanne, Switzerland. claudia.bagni@unil.ch.ORCID 0000-0002-4419-210X

Funding

Fondazione Telethon (Telethon Foundation) GGP20137Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 310030-182651Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) NCCR Synapsy 51NF40-158776
6 · The paper itself

Abstract

Autism Spectrum Disorder (ASD) is caused by genetic, epigenetic, and environmental factors. Mutations in the human FMR1 gene, encoding the Fragile X Messenger Ribonucleoprotein 1 (FMRP), cause the most common monogenic form of ASD, the Fragile X Syndrome (FXS). This study explored the interaction between the FMR1 gene and a viral-like infection as an environmental insult, focusing on the impact on core autistic-like behaviors and the mGluR1/5-mTOR pathway. Pregnant heterozygous Fmr1 mouse females were exposed to maternal immune activation (MIA), by injecting the immunostimulant Poly (I:C) at the embryonic stage 12.5, simulating viral infections. Subsequently, ASD-like behaviors were analyzed in the adult offspring, at 8-10 weeks of age. MIA exposure in wild-type mice led to ASD-like behaviors in the adult offspring. These effects were specifically confined to the intrauterine infection, as immune activation at later stages, namely puberty (Pubertal Immune Activation, PIA) at post-natal day 35 or adulthood (Adult Immune Activation, AIA) at post-natal day 56, did not alter adult behavior. Importantly, combining the Fmr1 mutation with MIA exposure did not intensify core autistic-like behaviors, suggesting an occlusion effect. Mechanistically, MIA provided a strong activation of the mGluR1/5-mTOR pathway, leading to increased LTP and downregulation of FMRP specifically in the hippocampus. Finally, FMRP modulates mTOR activity via TSC2. These findings further strengthen the key role of the mGluR1/5-mTOR pathway in causing ASD-like core symptoms.

Indexed as

Autism Spectrum DisorderFragile X Messenger Ribonucleoprotein 1Neuronal PlasticityTOR Serine-Threonine KinasesAnimalsDisease Models, AnimalFemaleFragile X SyndromeHippocampusMaleMiceMice, Inbred C57BLPoly I-CPregnancyPrenatal Exposure Delayed EffectsReceptor, Metabotropic Glutamate 5Fmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1metabotropic glutamate receptor type 1mTOR protein, mousePoly I-CReceptor, Metabotropic Glutamate 5Receptors, Metabotropic GlutamateTOR Serine-Threonine Kinases

Identifiers

PMID39604505
PMCPMC12014490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.